NFLIS-Drug Snapshot (June 2020)

Total Page：16

File Type：pdf, Size：1020Kb

snapshot NATIONAL FORENSIC LABORATORY INFORMATION SYSTEM DRUG June 2020 Newly Reported Drugs: The following drugs were reported to NFLIS-Drug for the first time between April 1, 2020, and June 30, 2020, and were submitted to a NFLIS participating laboratory on or after April 1, 2019. Northeast South 4-Anilino-1-Boc-piperidine Phenethyl 4-ANPP 2-Fluoro viminol MMB-4en-PINACA ADB-BUTINACA Snapshot of Drug Reports Top 5 Reported Drugs 257,376 Synthetic Cathinones 2,820 Selected Benzodiazepines 10,796 Received by NFLIS-Drug Methamphetamine 115,410 Eutylone 2,116 Flualprazolam 963 The tables on the right present Cannabis/THC 54,601 N-Ethylpentylone 135 Etizolam 832 1 the top five drug reports in each Cocaine 39,891 BMDP 135 Clonazolam 195 2 category received by NFLIS-Drug Heroin 25,263 Butylpentylone 99 Flubromazolam 81 Adinazolam 65 between April 1, 2020, and June Fentanyl 22,211 alpha-PiHP 83 30, 2020, that were submitted to a NFLIS participating laboratory Synthetic Cannabinoids 4,237 Narcotic Analgesics 16,953 Other Selected Drugs 4,507 on or after April 1, 2019. Fluoro-MDMB-PICA2 1,884 Oxycodone 4,820 MDMA 1,478 Fluoro-MDMB-BINACA2 633 Buprenorphine 4,780 Gabapentin 968 1 BMDP = 3,4-Methylenedioxy-N-benzylcathinone. MDMB-4en-PINACA 445 Hydrocodone 3,085 Lysergic acid diethylamide (LSD) 957 2 Includes all positional and nonspecified isomers as reported by participating laboratories. Fluoro-ADB2 98 Tramadol 1,721 Psilocin 825 FUB-AMB 96 Morphine 760 Xylazine 279 Emerging Drug Trends The charts below depict the number of reports (y axis) for selected emerging drugs that were submitted to a NFLIS participating laboratory from November 2018 through March 2020 and received by NFLIS-Drug by June 30, 2020. 35 20 APP-BINACA 3,4-Methylenedioxy PV8 0 0 80 20 Butylpentylone2 N-Ethylheptedrone 0 0 200 20 MDMB-4en-PINACA N-Butylhexedrone 0 0 20 20 Isotonitazene 5-MeO-DBT 0 0 Nov Jul Mar Nov Jul Mar ’18 ’19 ’20 ’18 ’19 ’20 Data Disclaimer: Substances identified by Federal, State, and local laboratories are included in the raw counts of drug reports received by NFLIS-Drug. Raw counts have not undergone any adjustments to account for laboratory nonresponse. Data for this publication were exported from the NFLIS-Drug database in July 2020 and include drug reports received by NFLIS-Drug through the end of June 2020. Because of the time it takes for a laboratory to analyze seized material and transfer the data to the NFLIS database, the data in this publication—unlike those reported in an Annual or Midyear Report—are not comprehensive and do not reflect total counts of drugs analyzed over the period. More information on NFLIS data limitations can be found in the NFLIS Questions and Answers guide: https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ ReportDownloads/Reports/2k17NFLISQA.pdf. NFLIS reports are available at https://www.nflis.deadiversion.usdoj.gov/Reports.aspx. Questions and comments: [email protected] DEA PRB 08-04-20-25.

Copy Link

Recommended publications

Product List March 2019 - Page 1 of 53
Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
[Show full text]
Slang Terms and Code Words: a Reference for Law Enforcement
UNCLASSIFIED Slang Terms and Code Words: A Reference for Law DEA Enforcement Personnel Intelligence DEA-HOU-DIR-022-18 July 2018 ReportBrief 1 UNCLASSIFIED UNCLASSIFIED DEA Intelligence Report Executive Summary This Drug Enforcement Administration (DEA) Intelligence Report contains new and updated information on slang terms and code words from a variety of law enforcement and open sources, and serves as an updated version to the product entitled “Drug Slang Code Words” published by the DEA in May 2017. It is designed as a ready reference for law enforcement personnel who are confronted with hundreds of slang terms and code words used to identify a wide variety of controlled substances, designer drugs, synthetic compounds, measurements, locations, weapons, and other miscellaneous terms relevant to the drug trade. Although every effort was made to ensure the accuracy and completeness of the information presented, due to the dynamics of the ever-changing drug scene, subsequent additions, deletions, and corrections are inevitable. Future addendums and updates to this report will attempt to capture changed terminology to the furthest extent possible. This compendium of slang terms and code words is alphabetically ordered, with new additions presented in italic text, and identifies drugs and drug categories in English and foreign language derivations. Drug Slang Terms and Code Wordsa Acetaminophen and Oxycodone Combination (Percocet®) 512s; Bananas; Blue; Blue Dynamite; Blueberries; Buttons; Ercs; Greenies; Hillbilly Heroin; Kickers; M-30s;
[Show full text]
Report of the International Narcotics Control Board for 2020 (E/INCB/2020/1) Is Supplemented by the Following Reports
INTERNATIONAL NARCOTICS CONTROL BOARD Report 2020 EMBARGO Observe release date: Not to be published or broadcast before Thursday 25 March 2021, at 1100 hours (CET) UNITED NATIONS CAUTION Reports published by the International Narcotics Control Board for 2020 TheReport of the International Narcotics Control Board for 2020 (E/INCB/2020/1) is supplemented by the following reports: Celebrating 60 Years of the Single Convention on Narcotic Drugs of 1961 and 50 Years of the Convention on Psychotropic Substances of 1971 (E/INCB/2020/1/Supp.1) Narcotic Drugs: Estimated World Requirements for 2021 — Statistics for 2019 (E/INCB/2020/2) Psychotropic Substances: Statistics for 2019 — Assessments of Annual Medical and Scientific Requirements for Substances in Schedules II, III and IV of the Convention on Psychotropic Sub- stances of 1971 (E/INCB/2020/3) Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psycho tropic Substances: Report of the International Narcotics Control Board for 2020 on the Implementation of Article 12 of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 (E/INCB/2020/4) The updated lists of substances under international control, comprising narcotic drugs, psycho tropic substances and substances frequently used in the illicit manufacture of narcotic drugs and psychotropic substances, are contained in the latest editions of the annexes to the statistical forms (“Yellow List”, “Green List” and “Red List”), which are also issued by the Board. Contacting the International Narcotics Control Board The secretariat of the Board may be reached at the following address: Vienna International Centre Room E1339 P.O.
[Show full text]
Examination of Antimicrobial Activity of Selected Non-Antibiotic Medicinal Preparations
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 69 No. 6 pp.1368ñ1371, 2012 ISSN 0001-6837 Polish Pharmaceutical Society EXAMINATION OF ANTIMICROBIAL ACTIVITY OF SELECTED NON-ANTIBIOTIC MEDICINAL PREPARATIONS HANNA KRUSZEWSKA1*, TOMASZ ZAR BA1 and STEFAN TYSKI1,2 1National Medicines Institute, Department of Antibiotics and Microbiology, 30-34 Che≥mska St., 00-725 Warszawa, Poland 2 Medical University of Warsaw, Department of Pharmaceutical Microbiology, 3 Oczki St., 02-007 Warszawa, Poland Abstract: The aim of this study was to detect and characterize the antimicrobial activity of non-antibiotic drugs, selected from the pharmaceutical products analyzed during the state control performed in National Medicines Institute, Warszawa, Poland. In 2010, over 90 pharmaceutical preparations have been randomly chosen from different groups of drugs. The surveillance study was performed on standard ATCC microbial strains used for drug control: S. aureus, E. coli, P. aeruginosa and C. albicans. It was shown that the drugs listed below inhib- ited growth of at least one of the examined strains: Arketis 20 mg tab. (paroxetine), Buvasodil 150 mg tab. (buflomedile), Halidor 100 mg tab. (bencyclane), Hydroxyzinum espefa 25 mg tab. (hydroxyzine), Norifaz 35 mg tab. (risedronate), Strattera 60 mg cap. (atomoxetine), Tamiflu 75 mg tab. (oseltamivir), Valpro-ratiopharm Chrono 300 mg tab. with longer dissolution (valproate), Vetminth oral paste 24 g+3 g/100 mL (niclozamide, oxybendazol). Strattera cap. showed broad activity spectrum. It inhibited growth of
[Show full text]
Report on a Novel Emerging Class of Highly Potent Benzimidazole NPS Opioids: Chemical and in Vitro Functional Characterization of Isotonitazene
Received: 29 August 2019 Revised: 12 November 2019 Accepted: 13 November 2019 DOI: 10.1002/dta.2738 RESEARCH ARTICLE Report on a novel emerging class of highly potent benzimidazole NPS opioids: Chemical and in vitro functional characterization of isotonitazene Peter Blanckaert1† | Annelies Cannaert2† | Katleen Van Uytfanghe2 | Fabian Hulpia3 | Eric Deconinck4 | Serge Van Calenbergh3 | Christophe Stove2 1Scientific Direction Epidemiology and Public Health, Section Lifestyle and Chronic Diseases, Abstract Belgian Early Warning System Drugs This paper reports on the identification and full chemical characterization of (BEWSD), Sciensano, Brussels, Belgium isotonitazene (N,N-diethyl-2-[5-nitro-2-({4-[(propan-2-yl)oxy]phenyl}methyl)-1H-ben- 2Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical zimidazol-1-yl]ethan-1-amine), a potent NPS opioid and the first member of the Sciences, Ghent University, Ghent, Belgium benzimidazole class of compounds to be available on online markets. Interestingly, 3Laboratory for Medicinal Chemistry, Department of Pharmaceutics, Faculty of this compound was sold under the name etonitazene, a structural analog. Identifica- Pharmaceutical Sciences, Ghent University, tion of isotonitazene was performed by gas chromatography mass spectrometry Ghent, Belgium (GC–MS) and liquid chromatography time-of-flight mass spectrometry (LC-QTOF- 4Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health MS), the latter identifying an exact-mass m/z value of 411.2398. All chromatographic Products, Sciensano, Brussels, Belgium data indicated the presence of a single, highly pure compound. Confirmation of the 1 13 Correspondence specific benzimidazole regio-isomer was performed using H and C NMR spectros- copy, after which the chemical characterization was finalized by recording Fourier- Christophe Stove, Laboratory of Toxicology, Department of Bioanalysis, Faculty of transform (FT-IR) spectra.
[Show full text]
Toxicology Cases: 10 Must-Have Drugs to Keep on Hand
Toxicology Cases: 10 Must-Have Drugs To Keep On Hand Acepromazine Atipamezole Cholestyramine Cyproheptadine Diazepam/ Midazolam Used in animals as a Commonly used to Useful for several Should be an additional For controlling mild sedative; much higher reverse dexmedetomidine toxins that undergo treatment for overdoses agitation or seizures from doses than normal may and xylazine. enterohepatic of serotonergic a variety of toxins. be needed when dealing Note: Can reverse recirculation: drugs such as SSRIs, Note: Should not be with amphetamine signs from other cholecalciferol (vitamin amphetamines, tramadol, used for overdoses of toxicosis. alpha agonists such as D3), sago palm, 5-HTP and marijuana amphetamines as it can clonidine, guanfacine, actually worsen clinical Note: Can also be used to cyanobacteria (blue when signs persist despite tizanidine, imidazoline signs. Also contraindicated help control hypertension green algae), digitoxin treatment with first-line and oxymetazoline for seizures caused by caused by stimulants when and some NSAIDs. drugs. decongestants; eye drops, muscimol (isoxazole) nitroprusside is not available and tick collars that contain Note: Some human Note: Only administer while mushroom ingestions. – start with small doses amitraz. and titrate to affect. Always formulations contain xylitol signs of serotonin syndrome monitor blood pressure. and those must not be used are present – most toxicity in dogs. cases only require 1-3 doses. Maropitant Methocarbamol N-Acetylcysteine Naloxone Propranolol Very effective at both For patients presenting Commonly used for Along with reversing Primarily used to treat stopping and preventing with tremors instead acetaminophen toxicosis; opioid exposure, can be sinus tachycardia vomiting. of seizures. Though can be given along used to reverse severe from chocolate, Note: Administration in expensive, there is with SAMe for other CNS depression from amphetamines, SSRIs, recumbent or neurologic nothing that will control hepatotoxins.
[Show full text]
Companion Animal Euthanasia Training Academy
Companion Animal Euthanasia Training Academy Oral and Injectable Pre-Euthanasia Sedatives/Anesthetics for Dogs and Cats Compiled in 2017 by Dr. Kathleen Cooney, U.S. CAETA instructor Disclaimer: These protocols are meant to provide options for sedation or anesthesia, ranging from mild to deep planes of sleep. Intraorgan injections are only permissible during periods of heavy sedation or anesthesia wherein the animal is pain-free and unaware the injection is occurring. When in doubt, CAETA recommends more drug be given to ensure a pain-free death. Giving sedative or anesthetic drugs to frail and compromised animals can result in adverse reactions or death itself. Drug and drug combinations can be administered intramuscular(IM) or subcutaneous (SQ) unless otherwise specified. Oral drugs may not elicite the desired depth of sleep every time. Many factors affect rate of absorption and uptake. Higher doses may be given initially or when it becomes clear the pet requires more. Dr. Cooney’s Injectable Protocols (IM and SQ) Dogs Sedation protocol (SQ preferred) • Dexmedetomidine (0.5mg/ml) = 0.1 ml per 10# minus 0.1ml (can decrease total by 0.2mls over 50# bw) [can substitute with Xylazine (100mg/ml) = 0.1ml per 10#] • Nalbuphine (20mg/ml) = 0.1 ml per 10# or Butorphanol (10mg/ml) = 0.1 ml per 10# • Acepromazine (10mg/ml) = 0.05 ml per 10# Anesthesia protocol • Telazol® (100mg/ml) = 0.1 ml per 10# • Acepromazine (10mg/ml) = 0.1 ml per 10# • Xylazine (100mg/ml) = 0.025 ml per 10# Cats Anesthesia protocol • Telazol®* (100mg/ml) = 0.15 ml for 2-5# 0.25 ml for 5-10# 0.3 ml for 10+# • Acepromazine (10mg/ml) = 0.1 ml for all BW Anesthesia protocol • Alfaxalone (10mg/ml) = 1.1 -1.5ml for most cats • Nalbuphine (20mg/ml) = 0.2ml for all BW • Acepromazine (10mg/ml)=0.1ml for all BW BW = body weight # = pounds mg = milligram ml = milliliter Various Other Injectable Protocols Shared by Veterinary Colleagues, compiled in 2016 Dogs 1.
[Show full text]
Kentucky Horse Racing Commission Withdrawal Guidelines Thoroughbred; Standardbred; Quarter Horse, Appaloosa, and Arabian KHRC 8-020-2 (11/2018)
Kentucky Horse Racing Commission Withdrawal Guidelines Thoroughbred; Standardbred; Quarter Horse, Appaloosa, and Arabian KHRC 8-020-2 (11/2018) General Notice Unless otherwise specified in these withdrawal guidelines or the applicable regulations and statutes, the following withdrawal guidelines are voluntary and advisory. The guidelines are recommendations based on current scientific knowledge that may change over time. A licensee may present evidence of full compliance with these guidelines to the Kentucky Horse Racing Commission (the “Commission” or “KHRC”) and the stewards as a mitigating factor to be used in determining violations and penalties. These withdrawal interval guidelines assume that administration of medications will be performed at doses that are not greater than the manufacturer’s maximum recommended dosage. Medications administered at dosages above manufacturer’s recommendations, in compounded formulations and/or in combination with other medications and/or administration inside the withdrawal interval may result in test sample concentrations above threshold concentrations that could lead to positive test results and the imposition of penalties. The time of administration of an orally administered substance, for the purposes of withdrawal interval, shall be considered to be the time of complete ingestion of the medication by the horse via eating or drinking. Brand names of medications, where applicable, are listed in parentheses or brackets following the generic name of a drug. In addition to the requirements contained in KRS Chapter 13A, the KHRC shall give notice of an amendment or addition to these withdrawal guidelines by posting the change on the KHRC website and at all Kentucky racetracks at least two weeks before the amendment or addition takes legal effect.
[Show full text]
Adrenoceptors Regulating Cholinergic Activity in the Guinea-Pig Ileum 1978) G.M
- + ! ,' Br. J. Pharmac. (1978), 64, 293-300. F'(O t.,," e reab- ,ellular PHARMACOLOGICAL CHARACTERIZATION OF THE PRESYNAPTIC _-ADRENOCEPTORS REGULATING CHOLINERGIC ACTIVITY IN THE GUINEA-PIG ILEUM 1978) G.M. Departmentof Pharmacology,Allen and HzmburysResearchLimited, Ware, Hertfordshire,SG12 ODJ I The presynaptic ct-adrenoceptors located on the terminals of the cholinergic nerves of the guinea- pig myenteric plexus have been characterized according to their sensitivities to at-adrenoceptor agonists and antagonists. 2 Electrical stimulation of the cholinergic nerves supplying the longitudinal muscle of the guinea-pig ! ileum caused a twitch response. Clonidine caused a concentration-dependent inhibition of the twitch i response; the maximum inhibition obtained was 80 to 95_o of the twitch response. Oxymetazoline and xylazine were qualitatively similar to clonidine but were about 5 times less potent. Phenylephrine and methoxamine also inhibited the twitch response but were at least 10,000 times less potent than clonidine. 3 The twitch-inhibitory effects of clonidine, oxymetazoline and xylazine, but not those of phenyl- ephrine or methoxamine, were reversed by piperoxan (0.3 to 1.0 lag/ml). 4 Lysergic acid diethylamide (LSD) inhibited the twitch response, but also increased the basal tone of the ileum. Mepyramine prevented the increase in tone but did not affect the inhibitory action of LSD. Piperoxan or phentolamine only partially antagonized the inhibitory effect of LSD. 5 Phentolamine, yohimbine, piperoxan and tolazoline were potent, competitive antagonists of the inhibitory effect of clonidine with pA2 values of 8.51, 7.78, 7.64 and 6.57 respectively. 6 Thymoxamine was a weak antagonist of clonidine; it also antagonized the twitch-inhibitory effect of morphine.
[Show full text]
Benzimidazole-Opioids June 2021
Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section Benzimidazole-Opioids June 2021 Introduction: metonitazene, metodesnitazene, and protonitazene involved interaction with β-arrestin-2. Mu-opioid receptor and β-arrestin-2 Recently, several synthetic substances of benzimidazole interaction has been implicated in adverse health effects of many structural class are being trafficked and abused for their opioid- opioid analgesics. It is well established that mu-opioid receptor like effects. In the late 1950s, the pharmaceutical research agonists have a high potential for addiction and can produce dose- laboratories of the Swiss chemical company CIBA dependent respiratory depression and arrest. Abuse of these Aktiengesellschaft synthesized numerous benzimidazole- benzimidazole-opioids has led to their positive identification in opioids to include butonitazene, etodesnitazene, flunitazene, several toxicological cases in the United States. Specifically, metonitazene, metodesnitazene, and protonitazene. Since metonitazene has been identified in twenty post-mortem cases. 2019, the abuse of benzimidazole-opioids as evidenced by their identification in toxicology cases, similar to other synthetic opioids, has resulted in adverse health effects including deaths. User Population: As the United States continues to experience an unprecedented The population likely to abuse benzimidazole-opioids appears to be epidemic of opioid misuse and abuse, the continued evolution the same as those abusing prescription opioid analgesics, heroin, and increased trafficking and popularity of new and deadly and other synthetic opioid substances. This is evidenced by the synthetic opioids including benzimidazole-opioids with no types of other drugs co-identified in isotonitazene seizures and in approved medical use are of public health concern. fatal overdose cases. Toxicology analyses co-identified some of these benzimidazole-opioids with other opioids, stimulants, and Chemistry: benzodiazepines.
[Show full text]
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
[Show full text]
Pharmaceutical Appendix to the Tariff Schedule 2
Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
[Show full text]